Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas

Modern Pathology

Volumn 10, Issue 10, 1997, Pages 963-968

  Sherman, Mark E ^a,b   Sturgeon, Susan ^b   Brinton, Louise A ^b   Potischman, Nancy ^b   Kurman, Robert J ^a   Berman, Michael L ^c   Mortel, Rodrigue ^d   Twiggs, Leo B ^e   Barrett, Rolland J ^f   Wilbanks, George D ^g  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e University of Minnesota   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g RUSH MEDICAL COLLEGE   (United States)

Author keywords

Endometrial carcinoma; Endometrioid; Hormones; Pathogenesis; Risk; Serous

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; ESTRONE; SEX HORMONE BINDING GLOBULIN;

ADULT; AGED; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CANCER RISK; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; SMOKING; UTERUS CARCINOMA;

AGE FACTORS; AGED; BODY MASS INDEX; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, PAPILLARY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; UTERINE NEOPLASMS;

EID: 0030862208     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Herrinton LJ, Weiss NS. Review. Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 1993;3:308-18.
2. Cauley JA, Gutai JP, Kuller LW, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-31.
3. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-56.
4. Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mostow ED, Schwartz PE, et al. A case-control study of cancer of the endometrium. Am J Epidemiol 1982;116:333-42.
5. La Vecchia C, Francheschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 1984;73:667-71.
6. Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 1990;39:266-71.
7. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
8. Chambers JT, Merino M, Kohorn El, Peschel RE, Schwartz PE. Uterine papillary serous carcinoma. Obstet Gynecol 1987;69:109-13.
9. Dunton CJ, Balsara G, McFarland M, Hernandez E. Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv 1991;46:97-102.
10. Gallion HH, van Nagel JR Jr, Powell DF, Donaldson ES, Higgins RV, Kryscio RJ, et al. Stage I serous papillary carcinoma of the endometrium. Cancer 1989;63:2224-8.
11. Goff BA, Kata D, Schmidt RA. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54:264-8.
12. Hendrickson M, Ross J, Eifel P, Cox RS, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
13. Lee KR, Belinson JL. Recurrence in noninvasive endometrial carcinoma. Am J Surg Pathol 1991;15:965-73.
14. Rosenberg P, Blom R, Hogberg T, Simonsen E. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol 1993;51:311-5.
15. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-10.
16. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990;3:120-8.
17. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995;19:417-32.
18. Walker AN, Mills SE. Serous papillary carcinoma of the endometrium. A clinicopathologic study of 11 cases. Diagn Gynecol Obstet 1982;4:261-7.
19. Kurman RJ, Kaminski PF, Norris HJ. The behavior of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
20. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
21. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
22. Bur ME, Perlman C, Edelman L. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7.
23. Jiko K, Sasano H, Ito K. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 1993;13:305-10.
24. Koshiyama M, Konishi I, Wang D, Mandai M, Komatsu T, Yamamoto S, et al. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlations with sex steroid receptor status. Virch Archiv A Pathol Anat Histopathol 1993;423:265-71.
25. Okamoto A, Sameshima Y, Yamada Y. Allelic loss on chromosome 19p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1991;51:5632-6.
26. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
27. Kohler MF, Berchuk A, Davidoff AM. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992; 52:1622-7.
28. Risinger JI, Dent GA, Ignar-Trowbridge D. p53 gene mutations in human endometrial carcinoma. Mol Carcinog 1992; 5:250-3.
29. Kohler MF, Nishii H, Humphrey PA, Sasaki H, Boyd JA, Marks JR, et al. Mutation of the p53 tumor suppressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol 1993;169:690-4.
30. Bohkman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1985;15:10-7.
31. Sherman ME, Sturgeon S, Brinton L, Kurman RJ. Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. J Cell Biochem 1995;23[Suppl]:160-4.
32. Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992;167:1317-25.
33. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, et al. A case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-35.
34. Creasman WT. New gynecologic cancer staging. Obstet Gynecol 1990;75:287-8.
35. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 4th ed. New York, NY: Springer-Verlag; 1994. p. 439-86.
36. Breslow NE, Day NE. Statistical methods in cancer research: the analysis of case-control studies [Pub. No. 32], Lyon, France: IARC Scientific; 1980.
37. Brinton LA, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD. Cigarette smoking and the risk of endometrial cancer. Am J Epidemiol 1993;137:281-91.
38. Umpierre SA, Burke TW, Tornos C, Ordonez N, Levenback C, Morris M. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 1994;13:127-30.
39. Bergeron C, Ferenczy A, Shyamala G. Distribution of estrogen receptors in various cell types of normal, hyperplastic, and neoplastic human endometrial tissues. Lab Invest 1988; 58:338-45.